Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Final Safety and Efficacy Data of Long-Term Open-Label Dosing of Subcutaneous (SC) Romiplostim in Children with Immune Thrombocytopenia (ITP)

Michael Tarantino, James B. Bussel, MD, Victor S. Blanchette, MD, Donald Beam, John Roy, Jenny M. Despotovic, DO, MS, Ashok Raj, Nancy Carpenter, Bhakti Mehta, Melissa Eisen

Blood (2017) 130 (Supplement 1): 14.

https://doi.org/10.1182/blood.V130.Suppl_1.14.14

Published: 2017

Journal Articles

A Single-Arm, Open-Label, Long-Term Efficacy and Safety Study of Subcutaneous (SC) Romiplostim in Children with Immune Thrombocytopenia (ITP)

John D. Grainger, MD MRCP, FRPATH, James B. Bussel, MD, Michael Tarantino, Nicola Cooper, MA, MD MRCP, FRCPath, Donald Beam, Jenny M. Despotovic, DO, MS, Alexey Maschan, MD PhD Professor, Nancy Carpenter, Melissa Eisen, Joseph Park

Blood (2017) 130 (Supplement 1): 2334.

https://doi.org/10.1182/blood.V130.Suppl_1.2334.2334

Published: 2017

Journal Articles

Romiplostim in Thrombocytopenic Patients with Low- or Int-1- Risk MDS Results in Reduced Bleeding without Impacting Leukemic Progression: Final Follow-up Results from a Randomized, Double-Blind, Placebo-Controlled Study

Hagop Kantarjian, Pierre Fenaux, Mikkael A. Sekeres, MD, Jeffrey Szer, Uwe Platzbecker, MD, Andrea Kuendgen, Gianluca Gaidano, Wieslaw Wiktor-Jedrzejczak, MD, Nancy Carpenter, Bhakti Mehta, Janet Franklin, Aristoteles Giagounidis

Blood (2016) 128 (22): 2000.

https://doi.org/10.1182/blood.V128.22.2000.2000

Published: 2016

Journal Articles

A Single-Arm, Open-Label, Long-Term Efficacy and Safety Study of Subcutaneous (SC) Romiplostim in Children with Immune Thrombocytopenia (ITP)

John Grainger, James B. Bussel, MD, Nichola Cooper, Michael Tarantino, Victor Blanchette, Jenny Despotovic, Alexey Maschan, MD PhD, Nancy Carpenter, Melissa Eisen, Bhakti Mehta

Blood (2016) 128 (22): 869.

https://doi.org/10.1182/blood.V128.22.869.869

Published: 2016

Journal Articles

Effect of Romiplostim on Health-Related Quality of Life in Children with Immune Thrombocytopenia and Associated Burden in Their Parents: Results from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study

Susan D Mathias, MPH, Xiaoyan Li, PhD, Melissa Eisen, MD, Nancy Carpenter, MSc, Ross D Crosby, PhD, Victor S. Blanchette, MD FRCP

Blood (2015) 126 (23): 37.

https://doi.org/10.1182/blood.V126.23.37.37

Published: 2015

Journal Articles

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety and Efficacy of Romiplostim in Children with Immune Thrombocytopenia (ITP)

Michael D Tarantino, MD, James B. Bussel, Victor S. Blanchette, Jenny Despotovic, Carolyn Bennett, Ashok Raj, MD, Bronwyn Williams, Donald Beam, Jaime Morales, Melissa J. Rose, Nancy Carpenter, Kun Nie, Melissa Eisen

Blood (2015) 126 (23): 7.

https://doi.org/10.1182/blood.V126.23.7.7

Published: 2015

Journal Articles

Pooled Analysis of Safety and Efficacy of Romiplostim in Splenectomized and Nonsplenectomized Patients (pts) with Immune Thrombocytopenia (ITP)

Francesco Rodeghiero, Andrew Provan, Michael Steurer, MD, Bertrand Godeau, MD, Nancy Carpenter, MSc, Georg Kreuzbauer, MD

Blood (2014) 124 (21): 4199.

https://doi.org/10.1182/blood.V124.21.4199.4199

Published: 2014

NARROW

Final Safety and Efficacy Data of Long-Term Open-Label Dosing of Subcutaneous (SC) Romiplostim in Children with Immune Thrombocytopenia (ITP)

A Single-Arm, Open-Label, Long-Term Efficacy and Safety Study of Subcutaneous (SC) Romiplostim in Children with Immune Thrombocytopenia (ITP)

Romiplostim in Thrombocytopenic Patients with Low- or Int-1- Risk MDS Results in Reduced Bleeding without Impacting Leukemic Progression: Final Follow-up Results from a Randomized, Double-Blind, Placebo-Controlled Study

A Single-Arm, Open-Label, Long-Term Efficacy and Safety Study of Subcutaneous (SC) Romiplostim in Children with Immune Thrombocytopenia (ITP)

Effect of Romiplostim on Health-Related Quality of Life in Children with Immune Thrombocytopenia and Associated Burden in Their Parents: Results from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety and Efficacy of Romiplostim in Children with Immune Thrombocytopenia (ITP)

Pooled Analysis of Safety and Efficacy of Romiplostim in Splenectomized and Nonsplenectomized Patients (pts) with Immune Thrombocytopenia (ITP)

Email alerts

ASH Publications

American Society of Hematology

Final Safety and Efficacy Data of Long-Term Open-Label Dosing of Subcutaneous (SC) Romiplostim in Children with Immune Thrombocytopenia (ITP)

A Single-Arm, Open-Label, Long-Term Efficacy and Safety Study of Subcutaneous (SC) Romiplostim in Children with Immune Thrombocytopenia (ITP)

Romiplostim in Thrombocytopenic Patients with Low- or Int-1- Risk MDS Results in Reduced Bleeding without Impacting Leukemic Progression: Final Follow-up Results from a Randomized, Double-Blind, Placebo-Controlled Study

A Single-Arm, Open-Label, Long-Term Efficacy and Safety Study of Subcutaneous (SC) Romiplostim in Children with Immune Thrombocytopenia (ITP)

Effect of Romiplostim on Health-Related Quality of Life in Children with Immune Thrombocytopenia and Associated Burden in Their Parents: Results from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety and Efficacy of Romiplostim in Children with Immune Thrombocytopenia (ITP)

Pooled Analysis of Safety and Efficacy of Romiplostim in Splenectomized and Nonsplenectomized Patients (pts) with Immune Thrombocytopenia (ITP)

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only